Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)

Background: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size,...

Full description

Bibliographic Details
Main Authors:	Nicolas Bertrand, MD, Pierre Guerreschi, MD, PhD, Nicole Basset-Seguin, MD, PhD, Philippe Saiag, MD, PhD, Alain Dupuy, MD, PhD, Sophie Dalac-Rat, MD, Véronique Dziwniel, PhD, César Depoortère, MD, Alain Duhamel, MD, PhD, Laurent Mortier, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	EClinicalMedicine
Subjects:	Locally advanced basal cell carcinoma Neoadjuvant Vismodegib
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537021001243

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021001243

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)

Internet

Similar Items